ATE419332T1 - Verfahren zur zellkultivierung in einer monoschicht - Google Patents

Verfahren zur zellkultivierung in einer monoschicht

Info

Publication number
ATE419332T1
ATE419332T1 AT01200292T AT01200292T ATE419332T1 AT E419332 T1 ATE419332 T1 AT E419332T1 AT 01200292 T AT01200292 T AT 01200292T AT 01200292 T AT01200292 T AT 01200292T AT E419332 T1 ATE419332 T1 AT E419332T1
Authority
AT
Austria
Prior art keywords
cells
medium
monolayer
culture
cultivation
Prior art date
Application number
AT01200292T
Other languages
English (en)
Inventor
Phillip J Provost
David L Krah
Paul A Friedman
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/893,295 external-priority patent/US5360736A/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE419332T1 publication Critical patent/ATE419332T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01200292T 1992-06-04 1993-05-27 Verfahren zur zellkultivierung in einer monoschicht ATE419332T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89403992A 1992-06-04 1992-06-04
US07/893,295 US5360736A (en) 1992-06-04 1992-06-04 Process for attenuated varicella zoster virus vaccine production

Publications (1)

Publication Number Publication Date
ATE419332T1 true ATE419332T1 (de) 2009-01-15

Family

ID=27129046

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01200292T ATE419332T1 (de) 1992-06-04 1993-05-27 Verfahren zur zellkultivierung in einer monoschicht
AT93201521T ATE206311T1 (de) 1992-06-04 1993-05-27 Verfahren zur herstellung von virusimpfstoff aus abgeschwächten varicella zoster viren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT93201521T ATE206311T1 (de) 1992-06-04 1993-05-27 Verfahren zur herstellung von virusimpfstoff aus abgeschwächten varicella zoster viren

Country Status (28)

Country Link
US (1) US5607852A (de)
EP (2) EP1097988B1 (de)
JP (2) JP2599552B2 (de)
KR (1) KR100350169B1 (de)
CN (2) CN1069216C (de)
AT (2) ATE419332T1 (de)
AU (2) AU4392193A (de)
BG (1) BG62176B1 (de)
CA (1) CA2097019C (de)
CZ (2) CZ289574B6 (de)
DE (2) DE69334254D1 (de)
DK (2) DK0573107T3 (de)
ES (2) ES2317869T3 (de)
FI (1) FI117758B (de)
GR (1) GR3036812T3 (de)
HU (1) HU220080B (de)
MX (1) MX9303274A (de)
NO (1) NO314068B1 (de)
NZ (1) NZ253527A (de)
PT (2) PT573107E (de)
RO (1) RO114906B1 (de)
RS (1) RS50330B (de)
RU (1) RU2126269C1 (de)
SK (1) SK279387B6 (de)
TW (1) TW349868B (de)
UA (1) UA27137C2 (de)
WO (1) WO1993024616A1 (de)
YU (1) YU49210B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2361495A (en) * 1994-04-28 1995-11-29 Aviron A novel vzv gene, mutant vzv and immunogenic compositions
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
US20040171152A1 (en) * 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
JP4543402B2 (ja) * 1996-10-10 2010-09-15 ライフ テクノロジーズ コーポレーション 植物由来栄養素を含む動物細胞培養培地
GB9716611D0 (en) * 1997-08-07 1997-10-08 Cantab Pharmaceuticals Res Ltd Virus preparations and methods
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
GB9804632D0 (en) 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
KR100378909B1 (ko) * 1998-03-18 2003-12-18 주식회사 엘지생명과학 사람세포주를이용한풍진백신의생산수율증대방법
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
WO1999057246A1 (en) * 1998-05-01 1999-11-11 Life Technologies, Inc. Animal cell culture media comprising non-animal or plant-derived nutrients
US20060286668A1 (en) * 1999-04-30 2006-12-21 Invitrogen Corporation Animal-cell culture media comprising non-animal or plant-derived nutrients
CA2359659C (en) * 2000-01-31 2006-10-17 The Research Foundation For Microbial Diseases Of Osaka University Method for quality control of an attenuated varicella live vaccine
CN1318580C (zh) * 2003-07-10 2007-05-30 北京科兴生物制品有限公司 可满足灭活疫苗生产的sars病毒规模化制备及灭活的方法
RU2259214C1 (ru) * 2004-01-28 2005-08-27 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения вакцины оспенной инактивированной сухой "оспавир"
US7344839B2 (en) * 2004-12-23 2008-03-18 Aurx, Inc. Virus preparations and methods
JP2010522536A (ja) * 2006-10-17 2010-07-08 メディミューン・エルエルシー ウイルス脂質成分の改変
US20080294361A1 (en) * 2007-05-24 2008-11-27 Popp Shane M Intelligent execution system for the monitoring and execution of vaccine manufacturing
CA2733399C (en) * 2008-08-11 2018-10-09 Sanofi Pasteur Biologics Co. Compositions and methods for the production of alpha-herpesviruses
CN101967466A (zh) 2009-07-28 2011-02-09 新泽西医学院 Orf7缺陷型水痘病毒株、含有该毒株的疫苗及其应用
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
CN101972474B (zh) * 2010-11-11 2012-06-27 长春祈健生物制品有限公司 冻干带状疱疹减毒活疫苗及制备方法
JP2014508522A (ja) * 2011-02-24 2014-04-10 モガム バイオテクノロジー リサーチ インスティチュート 新規な水痘帯状疱疹ウイルス株及びそれを用いた水痘及び帯状疱疹ウイルスワクチン
WO2014062060A1 (en) * 2012-10-18 2014-04-24 Erasmus University Medical Center Rotterdam New method for producing high titer cell-free vzv vaccine virus
CN103074304B (zh) * 2013-01-28 2016-01-13 江苏健安生物科技有限公司 高水平人二倍体细胞培养水痘-带状疱疹疫苗病毒方法
EP3041505A4 (de) * 2013-09-05 2017-04-19 Merck Sharp & Dohme Corp. Immunisierungsverfahren mit einem varicella-zoster-virus-antigen
CN103740735B (zh) * 2013-12-31 2016-04-06 李越希 化学合成的HSV2病毒gC糖蛋白胞外区基因片段及其表达、应用
AU2015357225B2 (en) * 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
RU2637093C1 (ru) * 2016-12-20 2017-11-29 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Способ получения живой культуральной аттенуированной вакцины для профилактики ветряной оспы
CN107174658B (zh) * 2017-04-29 2020-11-27 安徽智飞龙科马生物制药有限公司 人用水痘病毒灭活疫苗及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660565A (en) * 1968-04-17 1972-05-02 Wistar Inst Rubella vaccine and method
US3555149A (en) * 1968-07-05 1971-01-12 Merck & Co Inc Mumps vaccine and its preparation
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
JPS5341202B2 (de) * 1974-03-12 1978-11-01
US3961046A (en) * 1974-12-02 1976-06-01 American Cyanamid Company Mumps vaccine and preparation thereof
US4000256A (en) * 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
GB1481650A (en) * 1975-05-06 1977-08-03 Merck & Co Inc Chemical processes and products
JPS5251009A (en) * 1975-10-17 1977-04-23 Morinaga Milk Ind Co Ltd Method of producing drug for treating marrow leukemia
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
JPS5341202A (en) * 1976-09-28 1978-04-14 Fuji Photo Film Co Ltd Novel magnetic recording medium
JPS55147227A (en) * 1979-05-04 1980-11-17 Handai Biseibutsubiyou Kenkyukai Preparrtion of attenuated live mumps vaccine
US4252792A (en) * 1979-09-21 1981-02-24 Douglas Industries, Inc. Injectable rabies vaccine composition and method for preparing same
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS624370A (ja) * 1985-07-01 1987-01-10 Sharp Corp 半導体素子
US5024836A (en) * 1987-05-04 1991-06-18 Merck & Co., Inc. Stable lyophilized live herpes virus vaccine
WO1990003429A1 (en) * 1988-09-23 1990-04-05 Cetus Corporation Lipid microemulsions for culture media
US5360736A (en) * 1992-06-04 1994-11-01 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production

Also Published As

Publication number Publication date
RO114906B1 (ro) 1999-08-30
ES2317869T3 (es) 2009-05-01
FI117758B (fi) 2007-02-15
YU49210B (sh) 2004-09-03
CN1069216C (zh) 2001-08-08
MX9303274A (es) 1994-01-31
EP0573107A2 (de) 1993-12-08
FI945697A0 (fi) 1994-12-02
DE69334254D1 (de) 2009-02-12
CA2097019C (en) 2007-07-24
CZ304594A3 (en) 1995-10-18
KR100350169B1 (ko) 2004-05-20
NO314068B1 (no) 2003-01-27
EP0573107B1 (de) 2001-10-04
DK1097988T3 (da) 2009-05-04
AU673167B2 (en) 1996-10-31
HUT71863A (en) 1996-02-28
PT1097988E (pt) 2009-03-05
YU38893A (sh) 1996-02-19
GR3036812T3 (en) 2002-01-31
CN1082923A (zh) 1994-03-02
JPH06172215A (ja) 1994-06-21
RS50330B (sr) 2009-11-10
SK279387B6 (sk) 1998-10-07
CA2097019A1 (en) 1993-12-05
EP1097988B1 (de) 2008-12-31
AU4392193A (en) 1993-12-30
CZ289690B6 (cs) 2002-03-13
EP0573107A3 (de) 1995-04-26
DK0573107T3 (da) 2001-11-12
SK148094A3 (en) 1995-07-11
DE69330850T2 (de) 2002-04-11
BG62176B1 (bg) 1999-04-30
NO944654L (no) 1995-02-03
YU7504A (sh) 2006-08-17
NO944654D0 (no) 1994-12-02
EP1097988A1 (de) 2001-05-09
AU4003693A (en) 1993-12-09
WO1993024616A1 (en) 1993-12-09
RU2126269C1 (ru) 1999-02-20
UA27137C2 (uk) 2000-02-28
JPH09107958A (ja) 1997-04-28
BG99227A (bg) 1995-07-28
HU9403473D0 (en) 1995-02-28
FI945697L (fi) 1995-01-26
JP2599552B2 (ja) 1997-04-09
CZ289574B6 (cs) 2002-02-13
CN1307902A (zh) 2001-08-15
ATE206311T1 (de) 2001-10-15
TW349868B (en) 1999-01-11
DE69330850D1 (de) 2001-11-08
HU220080B (hu) 2001-10-28
ES2161702T3 (es) 2001-12-16
NZ253527A (en) 1996-09-25
US5607852A (en) 1997-03-04
PT573107E (pt) 2002-02-28
JP3156962B2 (ja) 2001-04-16

Similar Documents

Publication Publication Date Title
DE69334254D1 (de) Verfahren zur Zellkultivierung in einer Monoschicht
DE69637656D1 (de) Methoden zur Züchtung von Tierzellen
NO922887D0 (no) Fremgangsmaate for dannelse av cellemasse og/eller fermenteringsprodukter under sterile forhold samt anordning for utfoerelse av fremgangsmaaten
DE3681811D1 (de) Verfahren zur kontinuierlichen herstellung von l-carnitin.
DE69027962D1 (de) Vorrichtung und verfahren zur vermehrung in vivo und zellzucht in einem kulturmedium
Engel et al. Growth and autotrophic metabolism of Nitrosomonas europaea
ATE67787T1 (de) Verfahren zur herstellung von proteinen mittels induzierbarer expressionssysteme in in-vivovermehrten, genetisch modifizierten eukaryotischen wirtszellen.
ATE107690T1 (de) Methode zur züchtung und dafür geeignete vorrichtung.
DE69325449D1 (de) Verfahren zur entwicklung von neuen pflanzentypen mit kapazität zur stickstoffbindung ebenfalls in deren blättern
EP0380692A4 (en) Plant tissue culture process
ATE220714T1 (de) Verfahren zur herstellung von proteinen
DE69821343D1 (de) Verfahren zur steigerung des wachstums von pflanzenzellkulturen
NO991211D0 (no) Apparat for dyrking av mikroorganismer
EP0987324A3 (de) Zellwachstumsbeschleunigungsmittel enthaltende Polyphosphorsäure und Zellwachstumsmethode
DE69737409D1 (de) Verfahren zur Herstellung von L-Glutaminsäure durch kontinuierliche Gärung
KR920012425A (ko) 동물세포 배양용 고농도 배지 및 배양공정
ATE76251T1 (de) Verfahren zur kultur von pflanzengewebe.
EP0276154A3 (de) Methode und Apparat zur Züchtung von Zellen
EP0263659A3 (de) Gewebekulturmedien die L-Karnitin enthalten
JPS5668395A (en) Production of d(-)-beta-hydroxyisobutyric acid
RU2001123409A (ru) Способ культивирования микроорганизмов Mycobacterium tuberculosis
RU93045458A (ru) Способ культивирования галофильных бактерий
JPS6475096A (en) Removal method for tetramethylammonium compound

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1097988

Country of ref document: EP

EEFA Change of the company name